MicroRNA-486-5p and microRNA-486-3p: Multifaceted pleiotropic mediators in oncological and non-oncological conditions

Delihas, 2015, Discovery and characterization of the first non-coding RNA that regulates gene expression, micF RNA: a historical perspective, World J. Biol. Chem., 6, 272, 10.4331/wjbc.v6.i4.272

Anastasiadou, 2018, Non-coding RNA networks in cancer, Nat. Rev. Cancer, 18, 5, 10.1038/nrc.2017.99

Mizuno, 1984, A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA), Proc. Natl. Acad. Sci. U. S. A., 81, 1966, 10.1073/pnas.81.7.1966

Waters, 2009, Regulatory RNAs in bacteria, Cell, 136, 615, 10.1016/j.cell.2009.01.043

O'Brien, 2018, Overview of MicroRNA biogenesis, mechanisms of actions, and circulation, Front. Endocrinol., 9, 402, 10.3389/fendo.2018.00402

Rupaimoole, 2017, MicroRNA therapeutics: towards a new era for the management of cancer and other diseases, Nat. Rev. Drug Discov., 16, 203, 10.1038/nrd.2016.246

Losko, 2016, Long noncoding RNAs in metabolic syndrome related disorders, Mediat. Inflamm., 2016, 5365209, 10.1155/2016/5365209

Zampetaki, 2018, Long non-coding RNA structure and function: is there a link?, Front. Physiol., 9, 1201, 10.3389/fphys.2018.01201

Chen, 2010, Decoding the function of nuclear long non-coding RNAs, Curr. Opin. Cell Biol., 22, 357, 10.1016/j.ceb.2010.03.003

Bolha, 2017, Circular RNAs: biogenesis, function, and a role as possible cancer biomarkers, Int J Genomics, 2017, 6218353, 10.1155/2017/6218353

Ling, 2013, MicroRNAs and other non-coding RNAs as targets for anticancer drug development, Nat. Rev. Drug Discov., 12, 847, 10.1038/nrd4140

Li, 2018, MicroRNAs from plants to animals, do they define a new messenger for communication?, Nutr. Metab., 15, 68, 10.1186/s12986-018-0305-8

Skalsky, 2010, Viruses, microRNAs, and host interactions, Annu. Rev. Microbiol., 64, 123, 10.1146/annurev.micro.112408.134243

Hayder, 2018, MicroRNAs: crucial regulators of placental development, Reproduction, 155, R259, 10.1530/REP-17-0603

Liu, 2010, MicroRNA regulatory networks in cardiovascular development, Dev. Cell, 18, 510, 10.1016/j.devcel.2010.03.010

Issler, 2015, Determining the role of microRNAs in psychiatric disorders, Nat. Rev. Neurosci., 16, 201, 10.1038/nrn3879

Ha, 2014, Regulation of microRNA biogenesis, Nat. Rev. Mol. Cell Biol., 15, 509, 10.1038/nrm3838

Tanzer, 2004, Molecular evolution of a microRNA cluster, J. Mol. Biol., 339, 327, 10.1016/j.jmb.2004.03.065

Abd El-Maqsoud, 2016, Golgi phosphoprotein-3 and Y-Box-Binding protein-1 are novel markers correlating with poor prognosis in prostate cancer, Clin. Genitourin. Cancer, 14, e143, 10.1016/j.clgc.2015.12.015

Alarcon, 2015, N6-methyladenosine marks primary microRNAs for processing, Nature, 519, 482, 10.1038/nature14281

Khvorova, 2003, Functional siRNAs and miRNAs exhibit strand bias, Cell, 115, 209, 10.1016/S0092-8674(03)00801-8

Yang, 2010, Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis, Proc. Natl. Acad. Sci. U. S. A., 107, 15163, 10.1073/pnas.1006432107

Cheloufi, 2010, A dicer-independent miRNA biogenesis pathway that requires Ago catalysis, Nature, 465, 584, 10.1038/nature09092

Carthew, 2009, Origins and Mechanisms of miRNAs and siRNAs, Cell, 136, 642, 10.1016/j.cell.2009.01.035

Pisarello, 2015, MicroRNAs in the cholangiopathies: pathogenesis, diagnosis, and treatment, J. Clin. Med., 4, 1688, 10.3390/jcm4091688

Iorio, 2012, microRNA involvement in human cancer, Carcinogenesis, 33, 1126, 10.1093/carcin/bgs140

Shenouda, 2009, MicroRNA function in cancer: oncogene or a tumor suppressor?, Cancer Metastasis Rev., 28, 369, 10.1007/s10555-009-9188-5

Dharap, 2013, MicroRNA miR-324-3p induces promoter-mediated expression of RelA gene, PLoS One, 8, 10.1371/journal.pone.0079467

Pillai, 2005, MicroRNA function: multiple mechanisms for a tiny RNA?, RNA, 11, 1753, 10.1261/rna.2248605

Jo, 2015, Human Argonaute 2 has diverse reaction pathways on target RNAs, Mol. Cell, 59, 117, 10.1016/j.molcel.2015.04.027

Vasudevan, 2007, AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2, Cell, 128, 1105, 10.1016/j.cell.2007.01.038

Youness, 2016, Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression, Growth Factors, 34, 128, 10.1080/08977194.2016.1200571

Youness, 2016, MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc, Oncol Lett, 12, 2567, 10.3892/ol.2016.4914

Truesdell, 2012, MicroRNA-mediated mRNA translation activation in quiescent cells and oocytes involves recruitment of a nuclear microRNP, Sci. Rep., 2, 842, 10.1038/srep00842

Youness, 2019, Long non-coding RNAs: functional regulatory players in breast cancer, Noncoding RNA Res, 4, 36, 10.1016/j.ncrna.2019.01.003

Jemal, 2009, Cancer statistics, CA A Cancer J. Clin., 59, 225, 10.3322/caac.20006

Youness, 2018, A methoxylated quercetin glycoside harnesses HCC tumor progression in a TP53/miR-15/miR-16 dependent manner, Nat. Prod. Res., 1, 10.1080/14786419.2018.1509326

Shaalan, 2018, Destabilizing the interplay between miR-1275 and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma, Nat. Prod. Res., 32, 2217, 10.1080/14786419.2017.1366478

Rahmoon, 2017, MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients, Growth Factors, 35, 76, 10.1080/08977194.2017.1354859

Youness, 2018, A novel role of sONE/NOS3/NO signaling cascade in mediating hydrogen sulphide bilateral effects on triple negative breast cancer progression, Nitric Oxide, 80, 12, 10.1016/j.niox.2018.07.004

Awad, 2019, An acetylated derivative of vitexin halts MDA-MB-231 cellular progression and improves its immunogenic profile through tuning miR- 20a-MICA/B axis, Nat. Prod. Res., 1, 10.1080/14786419.2019.1686372

Calin, 2002, Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. U. S. A., 99, 15524, 10.1073/pnas.242606799

Jiang, 2018, MiR-486 as an effective biomarker in cancer diagnosis and prognosis: a systematic review and meta-analysis, Oncotarget, 9, 13948, 10.18632/oncotarget.24189

Gu, 2015, Aberrant placental villus expression of miR-486-3p and miR-3074-5p in recurrent miscarriage patients and uterine expression of these MicroRNAs during early pregnancy in mice, Gynecol. Obstet. Investig.

Peng, 2019, Long noncoding RNA DLGAP1-AS1 promotes cell proliferation in hepatocellular carcinoma via sequestering miR-486-5p, J. Cell. Biochem.

He, 2019, Role of miR-486-5p in regulating renal cell carcinoma cell proliferation and apoptosis via TGF-beta-activated kinase 1, J. Cell. Biochem., 120, 2954, 10.1002/jcb.26900

Li, 2018, Serum miR-486-5p as a diagnostic marker in cervical cancer: with investigation of potential mechanisms, BMC Canc., 18, 61, 10.1186/s12885-017-3753-z

Zappa, 2016, Non-small cell lung cancer: current treatment and future advances, Transl. Lung Cancer Res., 5, 288, 10.21037/tlcr.2016.06.07

Jin, 2019, MicroRNA-486-5p improves nonsmall-cell lung cancer chemotherapy sensitivity and inhibits epithelial-mesenchymal transition by targeting twinfilin actin binding protein 1, J. Int. Med. Res., 10.1177/0300060519850739

Kumar, 2011, Negative regulation of the tumor suppressor p53 gene by microRNAs, Oncogene, 30, 843, 10.1038/onc.2010.457

Hu, 2010, Negative regulation of tumor suppressor p53 by microRNA miR-504, Mol. Cell, 38, 689, 10.1016/j.molcel.2010.05.027

Yang, 2019, Expression of miR-486-5p and its signi fi cance in lung squamous cell carcinoma, J. Cell. Biochem., 120, 13912, 10.1002/jcb.28665

Xu, 2016, Colorectal cancer characterization and therapeutic target prediction based on microRNA expression profile, Sci. Rep., 6, 20616, 10.1038/srep20616

Liu, 2018, DNA-methylation-mediated silencing of miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/beta-catenin signal pathways, Cell Death Dis., 9, 1037, 10.1038/s41419-018-1105-9

Bjornetro, 2019, An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer, J. Extracell. Vesicles, 8, 1567219, 10.1080/20013078.2019.1567219

Tovar-Camargo, 2016, Exosomal microRNA biomarkers: emerging frontiers in colorectal and other human cancers, Expert Rev. Mol. Diagn, 16, 553, 10.1586/14737159.2016.1156535

Hon, 2017, Exosomes as potential biomarkers and targeted therapy in colorectal cancer: a mini-review, Front. Pharmacol., 8, 583, 10.3389/fphar.2017.00583

Liu, 2019, LncRNA XIST facilitates proliferation and epithelial-mesenchymal transition of colorectal cancer cells through targeting miR-486-5p and promoting neuropilin-2, J. Cell. Physiol., 234, 13747, 10.1002/jcp.28054

Zhang, 2014, MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells, Tumour Biol, 35, 11137, 10.1007/s13277-014-2412-0

Rask, 2014, Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status, Cell. Oncol., 37, 215, 10.1007/s13402-014-0176-6

Li, 2019, MiR-486-5p inhibits IL-22-induced epithelial-mesenchymal transition of breast cancer cell by repressing Dock1, J. Cancer, 10, 4695, 10.7150/jca.30596

Liu, 2010, MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors, J. Clin. Investig., 120, 1298, 10.1172/JCI39566

Chen, 2009, Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance, J. Natl. Compr. Cancer Netw., 7, 635, 10.6004/jnccn.2009.0044

Jedeszko, 2015, Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib, Sci. Transl. Med., 7, 282ra50, 10.1126/scitranslmed.3010722

Zarrabi, 2017, New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy, J. Hematol. Oncol., 10, 38, 10.1186/s13045-016-0374-y

Chen, 2015, Expression and prognostic value of miR-486-5p in patients with gastric adenocarcinoma, PLoS One, 10

Huang, 2015, MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1, FEBS J., 282, 579, 10.1111/febs.13167

Fransson, 2013, Stage-dependent expression of PI3K/Aktpathway genes in neuroblastoma, Int. J. Oncol., 42, 609, 10.3892/ijo.2012.1732

Sun, 2015, FGF9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells, BMC Canc., 15, 333, 10.1186/s12885-015-1353-3

Siegel, 2014, Cancer statistics, 2014, CA A Cancer J. Clin., 64, 9, 10.3322/caac.21208

Ma, 2016, miR-486-5p inhibits cell growth of papillary thyroid carcinoma by targeting fibrillin-1, Biomed. Pharmacother., 80, 220, 10.1016/j.biopha.2016.03.020

Ma, 2016, Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer, Oncotarget, 7, 10594, 10.18632/oncotarget.7236

Duan, 2014, Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma, J. Cell Mol. Med., 18, 863, 10.1111/jcmm.12232

Lightfoot, 2005, Aetiology of childhood leukemia, Bioelectromagnetics, S5, 10.1002/bem.20140

Zhang, 2013, Long non-coding RNA: a new player in cancer, J. Hematol. Oncol., 6, 37, 10.1186/1756-8722-6-37

Hassan, 2012, Recent updates on the role of microRNAs in prostate cancer, J. Hematol. Oncol., 5, 9, 10.1186/1756-8722-5-9

Liu, 2019, MiR-486-5p inhibits the proliferation of leukemia cells and induces apoptosis through targeting FOXO1, Mol. Cell. Probes, 44, 37, 10.1016/j.mcp.2019.02.001

Nakamura, 2008, Forkhead transcription factor FOXO subfamily is essential for reactive oxygen species-induced apoptosis, Mol. Cell. Endocrinol., 281, 47, 10.1016/j.mce.2007.10.007

Yang, 2017, The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways, Oncotarget, 8, 72835, 10.18632/oncotarget.20427

Jemal, 2011, Global cancer statistics, CA A Cancer J. Clin., 61, 69, 10.3322/caac.20107

Shiu, 2000, Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan, Br. J. Canc., 82, 1871, 10.1054/bjoc.2000.1208

Chou, 2019, MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1, J. Exp. Clin. Cancer Res., 38, 281, 10.1186/s13046-019-1283-z

Wang, 2019, Thrombospondin enhances RANKL-dependent osteoclastogenesis and facilitates lung cancer bone metastasis, Biochem. Pharmacol., 166, 23, 10.1016/j.bcp.2019.05.005

Ye, 2016, MiR-486-3p targeting ECM1 represses cell proliferation and metastasis in cervical cancer, Biomed. Pharmacother., 80, 109, 10.1016/j.biopha.2016.02.019

Steuer, 2017, An update on larynx cancer, CA A Cancer J. Clin., 67, 31, 10.3322/caac.21386

Hansen, 2013, Circular RNA and miR-7 in cancer, Cancer Res., 73, 5609, 10.1158/0008-5472.CAN-13-1568

Wang, 2019, Upregulation of circFLNA contributes to laryngeal squamous cell carcinoma migration by circFLNA-miR-486-3p-FLNA axis, Cancer Cell Int., 19, 196, 10.1186/s12935-019-0924-9

Savoy, 2013, The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it, Endocr. Relat. Cancer, 20, R341, 10.1530/ERC-13-0364

Aoi, 2013, Muscle-enriched microRNA miR-486 decreases in circulation in response to exercise in young men, Front. Physiol., 4, 80, 10.3389/fphys.2013.00080

Guehring, 2005, Stimulation of gene expression and loss of anular architecture caused by experimental disc degeneration--an in vivo animal study, Spine, 30, 2510, 10.1097/01.brs.0000186591.17114.e9

Zhang, 2017, Role of miR-155 in the regulation of MMP-16 expression in intervertebral disc degeneration, J. Orthop. Res., 35, 1323, 10.1002/jor.23313

Chai, 2019, miR-486-5p inhibits inflammatory response, matrix degradation and apoptosis of nucleus pulposus cells through directly targeting FOXO1 in intervertebral disc degeneration, Cell. Physiol. Biochem., 52, 109, 10.33594/000000008

Hansson, 2011, The immune system in atherosclerosis, Nat. Immunol., 12, 204, 10.1038/ni.2001

Niculescu, 2015, MiR-486 and miR-92a identified in circulating HDL discriminate between stable and vulnerable coronary artery disease patients, PLoS One, 10, 10.1371/journal.pone.0140958

Bardin, 2018, Emerging microRNA therapeutic approaches for cystic fibrosis, Front. Pharmacol., 9, 1113, 10.3389/fphar.2018.01113

Ideozu, 2019, Microarray profiling identifies extracellular circulating miRNAs dysregulated in cystic fibrosis, Sci. Rep., 9, 15483, 10.1038/s41598-019-51890-7

Terlizzi, 2018, Clinical expression of cystic fibrosis in a large cohort of Italian siblings, BMC Pulm. Med., 18, 196, 10.1186/s12890-018-0766-6

Ideozu, 2019, Transcriptome profiling and molecular therapeutic advances in cystic fibrosis: recent insights, Genes, 10, 10.3390/genes10030180

Mukai, 2018, Potential contribution of erythrocyte microRNA to secondary erythrocytosis and thrombocytopenia in congenital heart disease, Pediatr. Res., 83, 866, 10.1038/pr.2017.327

Wang, 2015, MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors, Blood, 125, 1302, 10.1182/blood-2014-06-581926

Chen, 2008, Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases, Cell Res., 18, 997, 10.1038/cr.2008.282

Giles, 2013, miRNA-7-5p inhibits melanoma cell migration and invasion, Biochem. Biophys. Res. Commun., 430, 706, 10.1016/j.bbrc.2012.11.086

Wei, 2016, MicroRNA 486-3P as a stability marker in acute coronary syndrome, Biosci. Rep., 36, 10.1042/BSR20160023

Goedert, 2015, NEURODEGENERATION. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein, Science, 349, 1255555, 10.1126/science.1255555

Wang, 2018, miR-486-3p influences the neurotoxicity of a-synuclein by targeting the SIRT2 gene and the polymorphisms at target sites contributing to Parkinson's disease, Cell. Physiol. Biochem., 51, 2732, 10.1159/000495963

Shibutani, 2017, Arid1b haploinsufficiency causes abnormal brain gene expression and autism-related behaviors in mice, Int. J. Mol. Sci., 18, 10.3390/ijms18091872

D'Gama, 2015, Targeted DNA sequencing from autism spectrum disorder brains implicates multiple genetic mechanisms, Neuron, 88, 910, 10.1016/j.neuron.2015.11.009

Yu, 2018, Serum miRNA expression profiling reveals miR-486-3p may play a significant role in the development of autism by targeting ARID1B, Neuroreport, 29, 1431, 10.1097/WNR.0000000000001107

Hoyer, 2012, Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability, Am. J. Hum. Genet., 90, 565, 10.1016/j.ajhg.2012.02.007

Byon, 2012, MicroRNAs: allies or foes in erythropoiesis?, J. Cell. Physiol., 227, 7, 10.1002/jcp.22729

Bauer, 2012, Reawakening fetal hemoglobin: prospects for new therapies for the beta-globin disorders, Blood, 120, 2945, 10.1182/blood-2012-06-292078

Sankaran, 2009, Developmental and species-divergent globin switching are driven by BCL11A, Nature, 460, 1093, 10.1038/nature08243

Lulli, 2013, MicroRNA-486-3p regulates gamma-globin expression in human erythroid cells by directly modulating BCL11A, PLoS One, 8, 10.1371/journal.pone.0060436

Han, 2016, Long noncoding RNA H19 indicates a poor prognosis of colorectal cancer and promotes tumor growth by recruiting and binding to eIF4A3, Oncotarget, 7, 22159, 10.18632/oncotarget.8063

Imig, 2015, miR-CLIP capture of a miRNA targetome uncovers a lincRNA H19-miR-106a interaction, Nat. Chem. Biol., 11, 107, 10.1038/nchembio.1713

Di Ianni, 2019, Ultrasound/microbubble-mediated targeted delivery of anticancer microRNA-loaded nanoparticles to deep tissues in pigs, J. Control. Release, 309, 1, 10.1016/j.jconrel.2019.07.024

Chipman, 2019, miRNA targeting: growing beyond the seed, Trends Genet., 35, 215, 10.1016/j.tig.2018.12.005

Li, 2014, Therapeutic targeting of microRNAs: current status and future challenges, Nat. Rev. Drug Discov., 13, 622, 10.1038/nrd4359